GlobeNewswire·Jul 16, 2026, 4:34 PM ET

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Judge Sheldon K. Rennie denied ANI Pharmaceuticals' post-trial motions for a new trial & judgment as a matter of law regarding unjust enrichment on July 16, 2026.
ANI intends to appeal the ruling to the Delaware Supreme Court while continuing to seek recovery of asset values sold to CG Oncology under the 2010 Agreement.
The company aims to secure a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec through its appeal.
ANI operates as a diversified biopharmaceutical company with business segments in Rare Disease, Generics, & Brands.
The press release includes standard forward-looking statements & risk factors regarding regulatory approvals, supply chain dependencies, & litigation outcomes.